Squarepoint
IBRX icon

Squarepoint’s ImmunityBio IBRX Stock Holding History

Squarepoint’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.66M Buy
+760,993
New +$5.76M 0.01% 1367
2026
Q1 		– Sell
-1,494,713
Closed -$2.96M – 4573
2025
Q4 		$2.96M Buy
1,494,713
+481,422
+48% +$1.09M ﹤0.01% 1806
2025
Q3 		$2.49M Buy
+1,013,291
New +$2.61M ﹤0.01% 1920
2024
Q4 		– Sell
-109,485
Closed -$407K – 5239
2024
Q3 		$407K Buy
109,485
+48,549
+80% +$225K ﹤0.01% 3253
2024
Q2 		$385K Buy
+60,936
New +$402K ﹤0.01% 3264
2024
Q1 		– Sell
-55,322
Closed -$278K – 4264
2023
Q4 		$278K Buy
+55,322
New +$174K ﹤0.01% 3409
2023
Q2 		– Sell
-481,915
Closed -$877K – 3756
2023
Q1 		$877K Buy
+481,915
New +$1.5M ﹤0.01% 1982
2022
Q3 		– Sell
-26,500
Closed -$99K – 3183
2022
Q2 		$99K Sell
26,500
-16,891
-39% -$67.8K ﹤0.01% 2622
2022
Q1 		$243K Sell
43,391
-16,814
-28% -$103K ﹤0.01% 2390
2021
Q4 		$366K Buy
+60,205
New +$452K ﹤0.01% 2344
2021
Q3 		– Sell
-62,550
Closed -$893K – 3140
2021
Q2 		$893K Buy
62,550
+50,050
+400% +$827K ﹤0.01% 1713
2021
Q1 		$297K Buy
+12,500
New +$324K ﹤0.01% 2404
2020
Q4 		– Sell
-38,571
Closed -$267K – 3067
2020
Q3 		$267K Buy
38,571
+26,194
+212% +$261K ﹤0.01% 1887
2020
Q2 		$152K Sell
12,377
-1,093
-8% -$6.17K ﹤0.01% 1907
2020
Q1 		$39K Buy
+13,470
New +$67.5K ﹤0.01% 1739
2018
Q4 		– Sell
-10,383
Closed -$38K – 2073
2018
Q3 		$38K Sell
10,383
-13,892
-57% -$43.9K ﹤0.01% 1927
2018
Q2 		$74K Buy
+24,275
New +$89.9K ﹤0.01% 1668
2016
Q1 		– Sell
-10,100
Closed -$175K – 1293
2015
Q4 		$175K Buy
+10,100
New +$150K 0.02% 1035

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Squarepoint's IBRX Position: Q2 2026 in Review

Squarepoint opened a new position in ImmunityBio (IBRX) in Q2 2026: 760,993 shares worth $6.66M. The stake represents 0.01% of the portfolio and ranks #1367 among its holdings. This is a return to the name: Squarepoint previously reported a position in IBRX as recently as Q4 2025.

Squarepoint first reported a position in IBRX in Q4 2015 and has held it in 18 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Squarepoint held 760,993 shares of ImmunityBio worth $6.66M as of Q2 2026.
  • ImmunityBio was a new Squarepoint position in Q2 2026.
  • ImmunityBio made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1367 holding.
  • Squarepoint first reported a position in ImmunityBio in Q4 2015 and has held it in 18 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.